1. Personalized medicine for lung cancer: new challenges for pathology;KM Kerr;Histopathology,2012
2. Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer;FR Hirsch;Clin Cancer Res,2010
3. Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status;J Douillard;Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status,2014
4. Peake, Mick. National Lung Cancer Audit Report 2014. http://www.hqip.org.uk/. 2014.
5. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance;E Gormally;Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance,2007